peter kolchinsky age

Prior to MRL Ventures, Josh was a Venture Partner with Atlas Venture and a Partner at Prism Venture Partners, focusing on company formation and seed and Series A investing. Prior to joining RAVen, Michael was the Executive Vice President and CMO at Point32Health, formed by the merger of Harvard Pilgrim Health Care and Tufts Health Plan. Joey ONeill is an Investor Services Associate at RA Capital Management. Jessica holds a BA in Linguistics from Brigham Young University and a PhD in auditory neuroscience from the Division of Medical Sciences at Harvard University. He received his doctorate in Organic Chemistry from Ohio University, and was a Fellow and Instructor in Department of Medicine, Boston University School of Medicine. Medicare 'negotiating' drug prices will hurt Americans, not help - STAT Maxs primary responsibilities at RA Capital are to work closely with the Investment Team to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. Before joining Proteon, Tim was the COO of Trine Pharmaceuticals and he held several management positions with GelTex Pharmaceuticals prior to its acquisition by Genzyme. Milind Deshpande is a Venture Partner at RA Capital, and President & CEO of Nayan Therapeutics, a RA Capital portfolio company. Bethany is a Senior Finance Associate at RA Capital Management. Peter Kolchinsky, Ph.D. is a biotechnology investor and a scientist. Brian has a B.S. Prior to MassTech, Natalie held varying Administrative roles at Northeastern University, Framingham Public Schools, and Bright Horizons Family Solutions. Prior to joining RA, Nadim was at NYU School of Medicine as Associate Dean of Therapeutics Alliances, a drug discovery accelerator that de-risks academic research towards partnerships with biopharma, investors, and nonprofits. Matthew holds a BS in Environmental Health Science from the University of Georgia and both a PhD in Biomedical Science and an MBA with a concentration in Finance from the University of Connecticut. Prior to joining RA, Emily was Chief Business Officer of Prevail Therapeutics from the companys inception in 2017 until its acquisition by Eli Lilly in 2021. Sophie led the cell therapy program, working with teams across the Trust to build capabilities to deliver industry and academically sponsored complex cell therapy trials for solid tumor cancer patients. In that role, Joel led teams responsible for advancing more than 40 compounds into clinical development, including Sprycel (dasatinib), which he co-invented. As Head of Vaccines, he is leading the RA vaccine team to support our evidence-based investment strategy. By accessing this website, you agree not to copy, reproduce, republish, upload, post, transmit, alter, or distribute, in any way, content or materials from this website in any manner inconsistent with the purposes for which it is offered without the prior written consent of RA Capital. Prior to joining RA Capital, Mario was Associate Vice President for Advanced Research at Sanofi Pasteur and Head of the team executing a strategy for integrating influenza vaccine development with machine learning and antigen design. Scott joins RA Ventures (RAVen) as Venture Partner and will be focusing on new company creation. Dr. Kolchinsky is a founding Partner and Portfolio Manager at RA Capital. Prior to Citigroup, he held various accounting and analyst roles at EY, Morgan Stanley, BBH, and Deloitte. She received a BA from Princeton University and an MBA from Harvard Business School. Matt Beverly is a Senior Software Engineer at RA Capital Management. Asthas primary responsibility is to identify needs for process improvement in the firm's data analytics and then both build and implement automated solutions. Peter Kolchinsky on Twitter Kriti Subramanyam is an Associate within the TechAtlas division of RA Capital Management. Mark Boshar is a Venture Partner at RA Ventures (RAVen), focusing on new company creation. At Corning, he held a number of sales and marketing roles with increasing responsibility; in his last position at Corning, Cony was responsible for marketing at a new business unit focused on high-throughput screening and molecular biology products. After joining RA Ventures as Chief Development Officer, Ed built the development team, oversaw development of six compounds from discovery-stage through to clinical-stage, and led the formation of several new companies, including Lusaris Therapeutics. Mario received postdoctoral training at the NIH and Mount Sinai School of Medicine in innate immunity and bioinformatics, earned a PhD in microbiology at University of Chile and a MS in Nuclear Physics. In this role he works closely with RAs Venture Team to evaluate various drug discovery platforms and initiate novel therapeutics programs. He continues advising both in a consultant capacity. Kate McKenna is a Compliance Associate at RA Capital Management. She also held research roles at MIT, Children's Hospital, Harvard, and Brigham and Women's Hospital. Abhishek has a BS in Bioproducts and Biosystems Engineering and a BS in Chemistry from University of Minnesota, Twin Cities. Within the last 20 years alone, PJ Hogan had a go with 2003's Peter Pan (a major, almost $100m-losing flop), Joe Wright tried again in 2015 with the more radical Pan (another massive failure . Brendan is a Tax Director at RA Capital Management. Tim was responsible for building the commercial team at GelTex and launching Renagel, a novel treatment for patients with kidney failure that grew to a $1B franchise . Habib Dable is a Venture Partner at RA Ventures (RAVen), focusing on advising and supporting newcos, portfolio companies and executives within RAVen. Mr. Grau earned his BA with High Honors from Davidson College, where he was awarded a Dana Honor Scholarship and elected to Phi Beta Kappa, and his MPhil, MA, and MAR degrees from Yale University, where he was awarded the Day Graduate Prize and was the recipient of a Mellon Fellowship in the Humanities. He earned his MS in Bioinformatics from Boston University. Ramin Farzaneh-Far is a Venture Partner at RA Capital where he works closely with RAs Venture Team to evaluate drug discovery platforms and initiate novel therapeutics programs. Prior to IGEN Cony worked for Corning in the US and in Europe. Natalie holds a BA in Psychology from William Paterson University and a MA in Psychology from Seton Hall University. He completed his residency in internal medicine at Yale-New Haven Hospital and completed his clinical gastroenterology fellowship at Massachusetts General Hospital / Harvard Medical School as well post-doctoral training with Frederick Alt, an HHMI investigator, in molecular immunology. Kyle was also the CEO and co-founder of Liquid Light, developer of a proprietary process to make major chemicals from CO2, which was sold to Avantium in 2016. Shan Shan holds a PhD in Neuroscience from Harvard University and a BS in Brain and Cognitive Sciences from MIT. Her doctoral research focused on bacteriophage-mediated regulation of bacterial transcription. Laura works on both public and private investments and serves as a Board Director for Artiva Biotherapeutics, Nimbus Therapeutics, and Acumen Pharmaceuticals. Anthony has a BS in Molecular and Cellular Biology from University of Arizona and a PhD in Genetics and Molecular Biology from University of North Carolina at Chapel Hill. Prior to Avilar, Mr. Grau was CEO at Sojournix, President at Heptares Therapeutics (acquired 2015), CEO at Cortria (acquired 2010), and COO at CombinatoRx (IPO 2005). The Kolchinskys came to the United States from Russia in 1981, when Peter was 4. Sarah teaches a course at Harvard Law School on venture capital fund formation. Jon's primary responsibilities at RA Capital are to work closely with the Investment Team to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. Prior to RA, Megan worked as a Gastroenterology Fellow at University of Pittsburgh Medical Center and a Resident Physician, Internal Medicine, at Beth Israel Deaconess Medical Center. While at BMS, Joel and his colleagues made notable advances in the area of kinase inhibitor drug discovery, particularly in immunology and oncology. Alonso Ricardo is an Entrepreneur in Residence at RA Capital, where he works closely with RAs Venture Team to evaluate drug discovery platforms and initiate novel therapeutics programs. Prior to RA, Gunes served as a scientist within the PCMM Program at Boston Childrens Hospital and her research focused on biophysical characterization of different amyloid fibrils. This website is for informational purposes only and does not constitute an offer to provide investment advisory or other services by RA Capital Management, L.P. (RA Capital). What is Peter Kolchinsky Net Worth? Currently, he serves as Chief Technology Officer at Danaher, with a focus on new genomic medicines. Prior to this role, Tom conducted research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities as a Senior Research Assistant. Peter Kolchinsky | RA Capital Management Profile - TipRanks.com Shan Shans primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. She also has a Master's in Accounting from Boston College and is a CPA. James is admitted to practice law in the Commonwealth of Massachusetts. Prior to RA, Drew gained experience in Data Science in Technical Consultant roles at ExxonMobil. All information is subject to change and may quickly become unreliable for various reasons, including changes in market conditions or economic circumstances. Phi previously worked as an Executive Assistant at Relay Therapeutics. Vikram Sheel Kumar is a Venture Partner at RA Capital where he is applying software to develop drugs and new ventures. Most recently, Tom served as Director of Operations at TPRV Capital, LP. Michael is chair of the Board of Managers of the Harvard Pilgrim Health Care Institute. Laura works on new company creation and early-stage investments, and serves as a Board Director for Be Biopharma, Expansion Therapeutics, Hemab, and Aliada Therapeutics. 4. Kathryn holds a BA in Geography and Peace and Conflict Studies from Colgate University, a MSc in International Development: Environment and Development from the University of Manchester (UK), and a MA and Ph.D. in Geography from Clark University (2016). Peter Kolchinsky's Post - LinkedIn Prior to that, Tom held an Operations Supervisor role at Bracebridge Capital, LLC and operations positions at Harvard Management Company and State Street Corporation. Brett holds a BS from Washington University, St. Louis and a JD from Duquesne University School of Law and is admitted to practice law in PA. Brett previously served as a Clerk for the Washington County Court of Common Pleas in PA. Emilie Schleer is the Senior Investor Relations Manager with the Operations Team at RA Capital Management. Peter Pan & Wendy review - Jude Law has fun in a so-so reinvention Prior to PwC, Brendan worked as Senior Tax Analyst for Highfields Capital Management LP and held tax and accounting positions at Citi and Investors Bank & Trust / State Street. In this role he works closely with the RA Ventures team to evaluate and incubate early stage therapeutic programs. Gunes holds a BSc in Biological Sciences and Bioengineering from Sabanci University, a MSc in Molecular and Cellular Biology and a PhD in Biochemistry from the University of Heidelberg. He is co-founder and CEO of Clear Creek Bio, an RA Capital portfolio company. Brigid was responsible for starting the venture fund and led investments in multiple sectors, including advanced analytics platforms, biomining and bioremediation, novel chemical leaching, long-duration energy storage, traceability of products, carbon removal, and green steel. Ally coached Women's Lacrosse at Muhlenberg College in PA. "Too old," said a man in his 70s. Patrick received his PhD in Natural Sciences, specifically Biochemistry and Molecular Biology, from the Leopold-Franzens University, Innsbruck, Austria. Dr. Ryan was also a fellow in Geriatric Psychiatry and Neuropsychiatry at Dartmouth-Hitchcock Medical Center. Peter founded and serves as a Director ofNo Patient Left Behind, a non-profit advocate for healthcare reforms that would make today's medicines affordable to patients and promote the innovation that gives all of us hope for tomorrow. Alyssa previously worked as a Senior Scientist at Eagle Pharmaceuticals. He holds a BS in Finance from Providence College. Joe brings to RA fifteen years of IT experience, beginning at the Apple Store and then transitioning to Boston Public Schools as an Apple Support Specialist. EMEA +44 20 7330 7500. Prior to this, Gerald was Director of Scientific Operations for RA Capital. Most importantly, this book describes concrete . Soumya obtained his PhD in X-ray Crystallography and Biophysics from the Indian Institute of Science while working as visiting research scholar at Rockefeller University. Rez holds a BSc in biochemistry and PhD in cell biology from Newcastle University, UK. Prior to joining Achillion, Milind was Group Leader at Bristol-Myers Squibb for all early stage discovery programs in infectious diseases and neuroscience. Peter Pan & Wendy supports the theory that Peter Pan is the real villain of his respective franchise with its depiction of the beloved Disney character. Prior to his time at Merck, Michael held discovery leadership roles at Immunext and Tolerx. He was Chief Medical Officer of Ra Pharmaceuticals from 2016 until it was acquired by UCB in 2020. Jaimie has a BS in Marketing Management from Coastal Carolina University. Ding Sun is a Senior Software Engineer at RA Capital Management. Jessica Sagers is Head of Engagement at RA Capital Management. and Ultragenyx Pharmaceuticals. Prior to joining RAVen, Habib spent five years as President and CEO at Acceleron Pharma. More recently, Scott founded MissionGBM, a global community and resource focused on advancing brain cancer therapeutics development and care delivery. Also joining the Board as observers are Nimish Shah, MPH, MBA, Vice President at Venrock, and Peter Kolchinsky, Ph.D., Managing Director of RA Capital Management. Previously, Tess held finance leadership roles at Foghorn Therapeutics, Wave Life Sciences, and Biogen. Tyler Kowalski is an InteractiveDesigner at RA Capital Management. Cristinas primary responsibility is to identifying compelling opportunities to help facilitate new company creation and early stage investing. James was an entrepreneur in residence at HealthCare Ventures, an advisor to Kurma Ventures, and is on the Scientific Advisory Board and Board of Directors of the Friedreichs Ataxia Research Alliance (FARA), a patient advocacy group. Fuads primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Cristina holds a BA in Molecular Biology with a minor in Business from Washington University in St. Louis, and a PhD in Microbiology and Molecular Genetics from Harvard University. The market worked. Michael Gillespie is an Analyst on the Venture Team at RA Capital Management. While in these roles, Emily helped Bluebird grow from 300 to 1000 employees. Phi's primary responsibilities at RA Capital are to support the Operations team by coordinating calendars, events, and company meetings. He holds BA and MA degrees in immunology from the University of Cambridge, an MD from University College London, and an MAS in clinical research from UCSF. Find Peter Kolchinsky's contact information, phone numbers, home addresses, age, background check, white pages, resumes and CV, places of employment, social media profiles, photos and videos, public records, arrest records, work history, news and business records . Zach previously worked as a Science Officer at the California Institute for Regenerative Medicine. She has published over fifty papers in peer reviewed journals. Christinas previous experience includes Stem Cell Program Manager at the Broad Institute and Deputy Editor at Cell Stem Cell. However he's a bit older than others, like Raquel Leviss, who is only 28 . Maryann received her Bachelor of Science in English from Northeastern University. Prior to joining RAVen, Joel was co-founder, President and Chief Scientific Officer at Jnana Therapeutics, a platform company focused on unlocking hard-to-drug targets. Brendan holds a MS in Accounting with a concentration in Taxation from Merrimack College and a BA in Economics from University of Massachusetts Amherst. Peter Kolchinsky - Managing Partner - RA Capital Management, LP - LinkedIn Previously, Shan Shan covered Orphan Heme, Orphan GOF, Vaccines, and various Gene Therapies as a Senior Associate. At BPS, Joe provided technical support for teachers and staff and was Jamf certified to manage Apple products. His primary responsibilities are to assist with accounting, financial reporting and investment valuation. Erin holds a Bachelor of Fine Arts degree from the Massachusetts College of Art & Design. Her graduate research investigated inhibitors of influenza virus and characterizing hydrophobic polycationic antimicrobial surfaces. Prior to joining RA, Jesse was Senior Director of Discovery at Kymera Therapeutics. Emilies primary responsibility at RA Capital is to manage current and potential investor relationships. Henry Stusnick is an Associate at RA Capital Management. By continuing, you accept the use of these cookies. Chris Morrison is an Editor at RA Capital Management. In this role, Gerald is responsible for evaluating new technology and novel biology to originate and support the generation of new companies in collaboration with RAVens Venture Partners and EIRs. Prior to joining biotech/pharma, she was a specialist in the corporate finance team at McKinsey & Co, focused on corporate transactions. Christinas primary responsibility is to edit and guide development of competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. As Engagement Associate at RA Capital Management, Thomas Culman leverages qualitative and quantitative skills to manage a variety of educational, outreach, and advocacy-oriented projects. Her graduate research investigated novel epigenetic regulators in glioblastoma. Prior to Bernstein, Joey held a Consultant role at FactSet. in Engineering Sciences in Bioengineering from Harvard University and a PhD in Medical Engineering and Medical Physics from the Harvard-MIT Health Sciences and Technology (HST) Program. Andrew is a Software Developer at RA Capital Management. Candice previously worked as the Director of Executive Office and Administration at Flywire. Ben previously worked as a Research Assistant in a Neuroinflammation lab at Brigham and Womens Hospital/Harvard Medical School, and was an Internet Application Developer at the Gallup Organization. Alex comes to RA from Mirai Advisory, where he specialized in financial risk and data science and developed machine learning algorithms to support banks managing regulatory and operational challenges. April 28, 2023 9:39am. Josh holds a BA in Chemistry from Williams College, an MD from the University of Pennsylvania School of Medicine, and an MBA from the Wharton School of Business. Emorys primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Elena has a BA in Molecular, Cellular, Developmental Biology from University of Colorado, Boulder and a PhD in Molecular, Cellular Biology and Biochemistry from Boston University. From 1997-2000, Scott served as General Manager of Biopharmaceuticals, Corporate Vice President of Business Development, and a member of the Board ofDirectors of Altus Pharmaceuticals, Inc (Nasdaq: ALTU). Adison is an Executive Assistant RA Capital Management. Dings primary responsibility at RA Capital is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Joel received his doctorate in Organic Chemistry from Columbia University and his bachelors in Chemistry from the University of Pennsylvania. Kats primary responsibility is supporting newcos, portfolio companies and executives within RAVen, focusing on strategic finance. Daphne Zohar is the founder and CEO of PureTech. Emily started her career in strategy consulting at Frankel Group. 'Too old': 80-year-old Biden works to combat worries about his age in

Guest Speaker Introduction, Bryan Mullins Wife, Landmark Merrick Park Food Menu, Cardiology At Springhill Hospital Mobile, Al, Articles P